Evidence map›Paper›PMID 40302965›Full record

ArticlePediatric diabetes2024

Detection of Islet Autoantibodies in Whole Blood by Antibody Detection by Agglutination-PCR (ADAP) Technology Is Sensitive and Suitable for General Population Screening Programs.

Tal Oron, Felipe de Jesus Cortez, Biana Shtaif, Peter V Robinson, Michal Yackobovitch-Gavan, Devangkumar Tandel, David Seftel, Moshe Phillip, Cheng-Ting Tsai, Galia Gat-Yablonski

Abstract read
In one paragraph

Article in Pediatric diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tal OronThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.ORCID 0000-0001-9485-2738
Felipe de Jesus CortezEnable Biosciences Inc., South San Francisco, CA, USA.
Biana ShtaifThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Peter V RobinsonEnable Biosciences Inc., South San Francisco, CA, USA.
Michal Yackobovitch-GavanThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Devangkumar TandelEnable Biosciences Inc., South San Francisco, CA, USA.
David SeftelEnable Biosciences Inc., South San Francisco, CA, USA.
Moshe PhillipThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.ORCID 0000-0002-6616-5612
Cheng-Ting TsaiEnable Biosciences Inc., South San Francisco, CA, USA.
Galia Gat-YablonskiThe Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.ORCID 0000-0002-2163-2176

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Detection of type 1 diabetes (T1D) at the preclinical stage is possible by detecting islet autoantibodies (IAs) years before the appearance of symptomatic diabetes. The Antibody Detection Israeli Research is a general population screening program searching for children with multiple IAs who are at risk of developing T1D. IAs are measured in capillary or venous whole blood (WB) samples using the novel ultrasensitive antibody detection by agglutination-PCR (ADAP) technology. Objective: To assess the accuracy and reliability of the ADAP assay in venous and capillary WB. Materials and Methods: In total, 50 children with T1D and 50 healthy controls participated in the study. Venous and capillary blood samples were drawn from participants with T1D, while only venous blood was drawn from the controls. The ADAP assay in venous and capillary blood was compared to the currently used assays in their ability to detect glutamic acid decarboxylase (GADA), islet antigen-2 (IA-2A), and insulin autoantibodies (IAAs). Results: The area under the curve using the receiver operating characteristic curves was comparable between the ADAP assay in WB and standard enzyme-linked immunosorbent assay (ELISA)/radioimmunoassay (RIA) for all three IAs GADA 0.946 (95% CI: 0.900-0.991) vs. 0.949 (0.906-0.992), Conclusions: The ADAP assay is reliable in detecting IA in venous and capillary WB samples with comparable performance to standard RIA and ELISA. These findings open avenues for widespread use of the ADAP assay in future general population screening programs to detect children at risk of developing T1D.

Indexed as

AutoantibodiesDiabetes Mellitus, Type 1Islets of LangerhansMass ScreeningPolymerase Chain ReactionAdolescentChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleGlutamate DecarboxylaseHumansInsulin AntibodiesMaleReceptor-Like Protein Tyrosine Phosphatases, Class 8Reproducibility of ResultsAutoantibodiesGlutamate DecarboxylaseInsulin AntibodiesReceptor-Like Protein Tyrosine Phosphatases, Class 8

Identifiers

PMID40302965
PMCPMC12016989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.